Lin YJ, Ou DL, Su YY, Hsu CL, et al. Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration. J Hepatol 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.
PMID: 40972843